Blog
Big Molecule Watch
September 18, 2024

Alteogen Seeks Approval for Aflibercept Biosimilar in Korea

Authors

On September 13, 2024, Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar of EYLEA®.  According to Alteogen, a 12-country Phase 3 study showed that ALT-L9 met its primary endpoint and demonstrated therapeutic equivalence to EYLEA®.

On July 1, 2024, Alteogen’s subsidiary, Altos Biologics, Inc., had submitted its Marketing Authorization Application to the European Medicines Agency (EMA) for ALT-L9.  Altos Biologics stated that it expects to receive approval from the EMA by 2025.

The post Alteogen Seeks Approval for Aflibercept Biosimilar in Korea appeared first on Big Molecule Watch.